These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31092459)

  • 1. Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
    Nakashima K; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Matsuo S; Mizokami A
    Anticancer Res; 2019 May; 39(5):2607-2614. PubMed ID: 31092459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
    BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
    Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
    Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
    Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
    Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
    Naito M; Ukai R; Hashimoto K
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
    Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
    Jadvar H; Challa S; Quinn DI; Conti PS
    Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
    Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
    Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
    van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radium-223 international early access program: results from the Spanish subset.
    Carles J; Méndez MJ; Pinto Á; Sáez MI; Arranz JA; Maroto P; López-Criado P; Mellado B; Donas JG; Hernando S; León L; Del Alba AG; Laínez N; Esteban E; Reynés G; Pérez-Gracia JL; Germà JR; López-Brea M; Pérez-Valderrama B; Moretones C; Castellano D
    Future Oncol; 2018 Jan; 14(1):41-50. PubMed ID: 29232987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response.
    Roque V; Jessop M; Pereira L; Gape P; Dizdarevic S; Sousa E; Carolino E
    Nucl Med Commun; 2019 Jun; 40(6):588-596. PubMed ID: 30908340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
    PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.